Chief Physician, Professor, Doctoral Supervisor. Currently serving as Vice President of Peking University Cancer Hospital, Deputy Director of the Department of Lymphatic Oncology, and Deputy Director of the Key Laboratory of the Ministry of Education. Recipient of the State Council Special Government Allowance. Visiting Scholar at the University of Nebraska Medical Center, USA. Social Affiliations: Chairman of the Lymphoma Expert Committee of the Chinese Society of Clinical Oncology (CSCO), Chairman of the Lymphatic and Hematologic Tumor Committee of the Beijing Anti-Cancer Association, Chairman of the Lymphoma Committee of the China Association for Promotion of Health Science and Technology, and Standing Committee Member of the Tumor Hematology Committee of the Chinese Anti-Cancer Association, among others. Professional Focus: Clinical diagnosis, treatment, and translational research in lymphoma. Possesses extensive clinical experience in lymphoma management, with expertise in developing individualized treatment plans for rare and refractory lymphomas by integrating targeted therapy, cellular immunotherapy, autologous transplantation, and other modalities. Collaborated with the team to establish a clinical research framework for novel lymphoma drugs and a basic translational research system, achieving significant improvements in lymphoma patient survival rates and quality of life. Has led or participated in over 300 domestic and international clinical registration studies, accounting for more than 75% of China's lymphoma drug development, with over 80% as lead investigator, providing opportunities for innovative drug clinical trials for patients with relapsed or refractory lymphoma. The team has facilitated the successful market approval of 31 new anti-lymphoma drugs or new indications, including China's first domestically developed innovative drug (BTK inhibitor) approved in the U.S., the first indications of four domestic PD-1 monoclonal antibodies, CAR-T cell therapy (with two patents for self-developed CAR-T), and the first domestic ADC drug. Basic and Translational Research: Focused on the field of lymphoma, covering pathogenesis, mechanisms of targeted drug resistance, exploration of novel immunotherapy targets, and the construction and application of lymphoma organoids. Has achieved substantial academic outcomes, including receiving the Second Prize of the Chinese Medical Science and Technology Progress Award. Has led 5 National Natural Science Foundation of China projects, 1 project on four major chronic diseases, 1 sub-project of the Ministry of Science and Technology's major special program, 1 key project of the Beijing Natural Science Foundation, and numerous other national and provincial-level scientific research projects. Has published over 100 papers in top international oncology and hematology journals such as *Lancet Haematology*, *Annals of Oncology*, and *Blood*. Over the years, has led the compilation and annual updates of the CSCO Lymphoma Guidelines, translated 3 academic monographs as the lead translator, and developed 2 standards related to dataset compilation.